COST-UTILITY OF DAPAGLIFLOZIN VERSUS DPP4 INHIBITORS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA

被引：0
|
作者：
Ordonez, J. E. [1 ]
机构：
[1] Univ Rosario, Bogota, DC, Colombia
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB52
引用
收藏
页码：A172 / A172
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY OF EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [2] SGLT2 versus DPP4 inhibitors for type 2 diabetes
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (03): : 168 - 170
  • [3] Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors
    Saito, Tatsuhiko
    Ohnuma, Kei
    Suzuki, Hiroshi
    Dang, Nam H.
    Hatano, Ryou
    Ninomiya, Hiroki
    Morimoto, Chikao
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 102 (01) : E8 - E12
  • [4] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [5] Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain
    Abad Paniagua, Eduardo Jose
    Casado Escribano, Pedro
    Fernandez Rodriguez, Jose Maria
    Morales Escobar, Francisco J.
    Betegon Nicolas, Lourdes
    Sanchez-Covisa, Joaquin
    Brosa, Max
    ATENCION PRIMARIA, 2015, 47 (08): : 505 - 513
  • [6] The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
    van der Linden, N.
    Van Olst, S.
    Nekeman, S.
    Uyl-de Groot, C. A.
    DIABETIC MEDICINE, 2021, 38 (04)
  • [7] DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS
    Van Olst, S. P.
    Nekeman, S.
    van der Linden, N.
    Uyl-de Groot, C. A.
    VALUE IN HEALTH, 2018, 21 : S132 - S132
  • [8] DETEMIR IN DIABETES TYPE 2 PATIENTS A COST-UTILITY ANALYSIS, COLOMBIA 2014
    Romero, M.
    Huerfano, L. M.
    Paez, M. L.
    Acero, G.
    VALUE IN HEALTH, 2015, 18 (03) : A63 - A63
  • [9] Clinical audit of patients using DPP4 inhibitors in longstanding type 2 diabetes
    Kumar, K. V. S. Hari
    Gupta, A. K.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2015, 9 (04) : 277 - 279
  • [10] Type 2 Diabetes: SGLT2 Inhibitors and DPP4 Inhibitors in Comparison
    Simon, Annika
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1002 - 1002
12345